India Validates First Indigenous HPV Test for Cervical Cancer Screening

Key Facts

• Truenat HR-HPV-Plus is India’s first indigenous HPV test validated for cervical cancer screening.
• Developed by Molbio Diagnostics, Goa, utilizing chip-based RT-PCR technology tailored for rapid and decentralized testing.
• The assay detects eight high-risk HPV genotypes, including types 16, 18, 52, and 58, which together account for over 95% of cervical cancer cases globally and in India.
• The validation study involved multiple Indian research institutions: AIIMS New Delhi, Indian Council of Medical Research (ICMR) institutes including NICPR and NIRRCH, and World Health Organization’s International Agency for Research on Cancer (IARC), France.
• The evaluation, involving 1,159 cervical samples, demonstrated the assay's high sensitivity and specificity, fulfilling international validation criteria by WHO and IARC.
• The development and validation were supported by the Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC) under the Grand Challenges India initiative.
• The test is designed for point-of-care application, enabling rapid screening near the patient without the need for centralized laboratory infrastructure.
• India has an annual burden of approximately 127,000 new cervical cancer cases and around 77,000 to 80,000 deaths.
• The indigenous Truenat platform is already widely used in India for infectious disease diagnosis, facilitating system familiarity among district healthcare workers for integration into cervical cancer screening programmes.
• An official announcement launching these indigenous HPV detection tests took place in Delhi on 23 April 2025, attended by Dr Jitendra Singh, Minister of State (Independent Charge) for Science and Technology.
• India’s national HPV vaccination campaign targets adolescent girls for prevention, while screening remains critical for women aged 30 years and above who are at risk or may have undetected infections.

Background & Context

Human papillomavirus (HPV) is a group of viruses with certain high-risk types linked causally to cervical cancer, a malignant disease affecting the cervix, the lower narrow part of the uterus. Persistent infection with high-risk HPV types is necessary but not sufficient for cervical cancer development, with cofactors influencing progression. Identification of precancerous lesions via cytology is limited by sensitivity; molecular HPV DNA testing improves early detection, triage, treatment selection, and follow-up.

India carries a disproportionate share of cervical cancer cases globally (nearly 25%). While HPV vaccination is the cornerstone of primary prevention, secondary prevention through screening remains essential due to existing at-risk populations. Current screening technologies have limitations in resource-limited settings, and indigenous, affordable, rapid tests enhance feasibility and coverage.

Why This Matters for Exams / Exam Relevance

Understanding India's step towards self-reliant healthcare innovation through indigenous HPV screening technology is relevant for competitive exams in sections like Health, Science & Technology, and Government Initiatives. Key facts like the involvement of AIIMS, ICMR, WHO-IARC, the DBT-BIRAC Grand Challenges India initiative, and the technology type (chip-based RT-PCR) are often test points. Also, knowing cervical cancer statistics and the role of HPV types supports general awareness topics.

Points to Remember

• Truenat HR-HPV-Plus is India's first indigenous HPV test for cervical cancer screening, validated in 2025.
• Detects eight high-risk HPV genotypes, which account for approximately 95% of cervical cancer cases, including types 16, 18, 52, and 58 prevalent in India.
• Development led by Molbio Diagnostics (Goa) and validated in collaboration with AIIMS New Delhi, ICMR institutes, and WHO’s IARC.
• Test meets WHO and IARC international validation standards.
• Utilizes chip-based RT-PCR technology optimized for point-of-care testing, enabling use in decentralized, low-resource settings.
• Supported by DBT-BIRAC under the Grand Challenges India initiative promoting biotechnology innovations.
• Officially announced on 23 April 2025 in Delhi, aligning with national HPV vaccination drives.
• India faces about 127,000 new cervical cancer cases and up to 80,000 deaths annually, making screening a critical public health need.
• HPV vaccination programs target prevention in adolescent girls; screening focuses on women over 30 years for early detection and management.